Bernard A. Fox, PhD, has served as the president and chief executive officer since founding the company in 2005. He served on the board of directors of NeoPharm from 2004 to 2010, and is currently on the board of directors of the Oregon Bioscience Association. Dr. Fox also co-founded UbiVac-CMV, a company developing cytomegalovirus vectors as vaccines for cancer. A recognized expert in cancer immunotherapy, he served/serves on Advisory Boards for AstraZeneca, Bristol-Meyers Squibb, Cell Genesys, Dendreon, EMD Serono, Janssen/Johnson and Johnson, MannKind, Micromet, Novartis, PerkinElmer and Pfizer.
He received his BS and MS degrees from the University of Detroit and his PhD from Wayne State University. His fellowship training was with Dr. Steven A. Rosenberg, at the National Cancer Institute, National Institutes of Health, Bethesda, MD. Dr. Fox is an internationally recognized expert on cancer immunotherapy and maintains his position as the Harder Family Endowed Chair for Cancer Research, member and Chief, Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.
He is also a member and co-leader of the Tumor Immunology Focus Panel for the Knight Cancer Institute and adjunct associate professor, Department of Molecular Microbiology and Immunology, Oregon Health and Science University.
Dr. Fox brings to UbiVac his experience in moving basic science advances from the bench to the bedside. He has received funding from the National Cancer Institute, Department of Defense, Prostate Cancer Foundation and several other foundations. He has published more than 120 manuscripts and book chapters, served on review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, and serves on editorial boards of seven scientific journals.
Dr. Fox is past president of the Society for Immunotherapy of Cancer and is current chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations.back to speakers